Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 252

1.

Paroxetine in the first trimester and the prevalence of congenital malformations.

Cole JA, Ephross SA, Cosmatos IS, Walker AM.

Pharmacoepidemiol Drug Saf. 2007 Oct;16(10):1075-85.

PMID:
17729379
2.

Bupropion in pregnancy and the prevalence of congenital malformations.

Cole JA, Modell JG, Haight BR, Cosmatos IS, Stoler JM, Walker AM.

Pharmacoepidemiol Drug Saf. 2007 May;16(5):474-84.

PMID:
16897811
3.

First trimester exposure to paroxetine and risk of cardiac malformations in infants: the importance of dosage.

Bérard A, Ramos E, Rey E, Blais L, St-André M, Oraichi D.

Birth Defects Res B Dev Reprod Toxicol. 2007 Feb;80(1):18-27.

PMID:
17187388
4.

Paroxetine and congenital malformations: meta-Analysis and consideration of potential confounding factors.

Bar-Oz B, Einarson T, Einarson A, Boskovic R, O'Brien L, Malm H, Bérard A, Koren G.

Clin Ther. 2007 May;29(5):918-26. Review.

PMID:
17697910
5.

SSRI antidepressants and birth defects.

[No authors listed]

Prescrire Int. 2006 Dec;15(86):222-3.

PMID:
17167929
6.

Valproic acid monotherapy in pregnancy and major congenital malformations.

Jentink J, Loane MA, Dolk H, Barisic I, Garne E, Morris JK, de Jong-van den Berg LT; EUROCAT Antiepileptic Study Working Group.

N Engl J Med. 2010 Jun 10;362(23):2185-93. doi: 10.1056/NEJMoa0907328. Review.

7.

Duration of antidepressant use during pregnancy and risk of major congenital malformations.

Ramos E, St-André M, Rey E, Oraichi D, Bérard A.

Br J Psychiatry. 2008 May;192(5):344-50. doi: 10.1192/bjp.bp.107.042523.

8.

First trimester paroxetine use and the prevalence of congenital, specifically cardiac, defects: a meta-analysis of epidemiological studies.

Wurst KE, Poole C, Ephross SA, Olshan AF.

Birth Defects Res A Clin Mol Teratol. 2010 Mar;88(3):159-70. doi: 10.1002/bdra.20627.

PMID:
19739149
9.

Evaluation of the risk of congenital cardiovascular defects associated with use of paroxetine during pregnancy.

Einarson A, Pistelli A, DeSantis M, Malm H, Paulus WD, Panchaud A, Kennedy D, Einarson TR, Koren G.

Am J Psychiatry. 2008 Jun;165(6):749-52. doi: 10.1176/appi.ajp.2007.07060879. Epub 2008 Apr 1. Erratum in: Am J Psychiatry. 2008 Sep;165(9):1208. Am J Psychiatry. 2008 Jun;165(6):777.

PMID:
18381907
10.
11.

Maternal use of selective serotonin re-uptake inhibitors in early pregnancy and infant congenital malformations.

Källén BA, Otterblad Olausson P.

Birth Defects Res A Clin Mol Teratol. 2007 Apr;79(4):301-8.

PMID:
17216624
12.

First-trimester use of paroxetine and congenital heart defects: a population-based case-control study.

Bakker MK, Kerstjens-Frederikse WS, Buys CH, de Walle HE, de Jong-van den Berg LT.

Birth Defects Res A Clin Mol Teratol. 2010 Feb;88(2):94-100. doi: 10.1002/bdra.20641.

PMID:
19937603
13.

Risks of congenital malformations and perinatal events among infants exposed to antidepressant medications during pregnancy.

Davis RL, Rubanowice D, McPhillips H, Raebel MA, Andrade SE, Smith D, Yood MU, Platt R; HMO Research Network Center for Education, Research in Therapeutics.

Pharmacoepidemiol Drug Saf. 2007 Oct;16(10):1086-94. Review.

PMID:
17729378
14.

Increased rate of major malformations in offspring exposed to valproate during pregnancy.

Wyszynski DF, Nambisan M, Surve T, Alsdorf RM, Smith CR, Holmes LB; Antiepileptic Drug Pregnancy Registry.

Neurology. 2005 Mar 22;64(6):961-5.

PMID:
15781808
15.

Perinatal outcome following third trimester exposure to paroxetine.

Costei AM, Kozer E, Ho T, Ito S, Koren G.

Arch Pediatr Adolesc Med. 2002 Nov;156(11):1129-32.

PMID:
12413342
16.

Antidepressant medication use and risk of persistent pulmonary hypertension of the newborn.

Andrade SE, McPhillips H, Loren D, Raebel MA, Lane K, Livingston J, Boudreau DM, Smith DH, Davis RL, Willy ME, Platt R.

Pharmacoepidemiol Drug Saf. 2009 Mar;18(3):246-52. doi: 10.1002/pds.1710.

PMID:
19148882
17.

Paroxetine exposure during pregnancy and cardiac malformations.

Scialli AR.

Birth Defects Res A Clin Mol Teratol. 2010 Mar;88(3):175-7. doi: 10.1002/bdra.20655. No abstract available.

PMID:
20175190
18.

Major congenital malformations after first-trimester exposure to ACE inhibitors.

Cooper WO, Hernandez-Diaz S, Arbogast PG, Dudley JA, Dyer S, Gideon PS, Hall K, Ray WA.

N Engl J Med. 2006 Jun 8;354(23):2443-51.

19.

Fetal effects of anticonvulsant polytherapies: different risks from different drug combinations.

Holmes LB, Mittendorf R, Shen A, Smith CR, Hernandez-Diaz S.

Arch Neurol. 2011 Oct;68(10):1275-81. doi: 10.1001/archneurol.2011.133. Epub 2011 Jun 13.

PMID:
21670385
20.

Selective serotonin reuptake inhibitors and risk for major congenital anomalies.

Malm H, Artama M, Gissler M, Ritvanen A.

Obstet Gynecol. 2011 Jul;118(1):111-20. doi: 10.1097/AOG.0b013e318220edcc.

PMID:
21646927
Items per page

Supplemental Content

Write to the Help Desk